Miot C, Dana M, Desprez-Curely J P, Koskas Y, Weil M, Dumont J, Bernard J
J Radiol. 1979 May;60(5):333-8.
In our 98 patients all treated by association chemotherapy + cobaltherapy, 37 cases were stages III and IV and 71 cases were of diffuse pathology classification. Meanwhile the results were not so poor: 66% at 5 years survival (all stages) and 69% for stages I and II. The curves of survival rate generally stabilize at 7 years. The prognostic depend of the pathology class: diffuse LBS and diffuse HBS have an evolution similar to acute leukemia (44.5% and 19% at 7 years survival), on the opposite nodular LBS, diffuse LCS have 100% survival at 7 years. Diffuse cases have visceral relapses (liver, bone marrow, Waldeyer ring) or generalized lymphatic involvement; nodular cases have generally localized and only lymph-nodes relapses. The best results by large fields irradiation suggest a contiguous extension of the disease, but there is also distant lymph nodes relapses. In the nodular cases, relapses can be generally cured by localized radiotherapy. In the diffuse case, we do not know if it is better to give total lymphnode irradiation (or to give more chemotherapy with economic irradiation). 10 gastro-intestinal cases were treated by moving strip technique with excellent tolerance and 67.5% at 5 years survival. These results show that interesting results may be obtained in non Hodgkin lymphomas by association of chemotherapy, with selective and moderately large fields irradiation, even in disseminated cases, even in diffuse cases.
在我们全部接受联合化疗加钴胺疗法治疗的98例患者中，37例为Ⅲ期和Ⅳ期，71例为弥漫性病理分类。同时，结果并非很差：5年生存率为66%（所有分期），Ⅰ期和Ⅱ期为69%。生存率曲线一般在7年时趋于稳定。预后取决于病理类型：弥漫性淋巴细胞性Burkitt淋巴瘤（LBS）和弥漫性组织细胞性淋巴瘤（HBS）的病程发展类似于急性白血病（7年生存率分别为44.5%和19%），相反，结节性LBS、弥漫性淋巴细胞性肉瘤（LCS）7年生存率为100%。弥漫性病例有内脏复发（肝脏、骨髓、韦氏环）或全身性淋巴结受累；结节性病例一般为局部复发，仅为淋巴结复发。大野照射的最佳结果提示疾病有连续性扩展，但也有远处淋巴结复发。在结节性病例中，复发一般可通过局部放疗治愈。在弥漫性病例中，我们不知道给予全淋巴结照射（或给予更多化疗并辅以经济的照射）是否更好。10例胃肠道病例采用移动条技术治疗，耐受性良好，5年生存率为67.5%。这些结果表明，即使在播散性病例、甚至弥漫性病例中，联合化疗并辅以选择性和适度大野照射，在非霍奇金淋巴瘤中也可能获得令人满意的结果。
